Subject Index

A

Acebutolol
  hypertension 7: 94
Adipose tissue
  drug action 7: 141–142
Adrenergic receptors
  beta-blocking drugs 7: 9–10
Alcoholism
  propranolol 7: 140
α-Adrenergic receptor blocking drugs
  + beta-blocking drugs in hypertension 7: 94
Alprenolol
  absorption 7: 40
  asthma 7: 132–136
  angina pectoris 7: 61, 67–69, 75–76, 78
  bioavailability 7: 40–41
  clearance 7: 42–43
  elimination 7: 40
  half life, clearance 7: 42–43
  hear syndrome hyperkinetic 7: 110
  hypertension 7: 92, 96–98
  hyperthyroidism 7: 50
  pharmacodynamics 7: 8–38
  plasma binding 7: 43
  respiratory function 7: 130–136
  side-effects 7: 98–102
Androgens
  erythropoiesis 7: 150–151
Angina pectoris
  beta-blocking drugs 7: 55–84
  drug trials 7: 59–61, 63–67, 73
Antidepressants, tricyclic
  continuation therapy 7: 147
Antiparkinsonian drugs
  dyskinesia, tardive 7: 148
Asthma
  beta-blocking drugs 7: 98–99, 124–125

B

β-Adrenergic receptor blocking drugs
  absorption 7: 40
  agonist activity 7: 10–11
  angina pectoris 7: 55–84
    antianginal activity 7: 61–63
    dosage regulation 7: 79
    drug trials 7: 59–61, 63–67, 73
    mode of action 7: 57–59
    nitrates comparison 7: 76–78
    precautions 7: 78–79
    therapeutic trials 7: 67–78
    therapeutic use 7: 80–81
    verapamil comparison 7: 78
  arterial pressure 7: 28
  asthma 7: 98–99, 124–125, 132–136
  atrioventricular conduction 7: 23–24
  β-blocking effect 7: 10
  bioavailability 7: 40–41, 45
  blood flow 7: 24–26
  bronchoconstriction: mechanism 7: 131
  carbohydrate metabolism 7: 31–32
  cardiac failure 7: 99–100, 122
  cardiac output 7: 18–23, 26–27
  cardiomyopathy, hypertrophic 7: 107–109

cardiovascular haemodynamic
effects 7: 12–29
children 7: 45
clearance 7: 42–43
elimination 7: 40–41
Fallot's tetralogy 7: 114–115
fatty acids, free 7: 31–32
growth hormone 7: 32–33
haematological reactions 7: 126
half-life, excretion 7: 42–43
heart rate: effect on 7: 15–18
heart syndrome, hyperkinetic 7: 110–114
hypertension 7: 85–105
clinical use 7: 96–98
combined with other drugs 7: 94
dosage 7: 94
drug trials 7: 89–90
mode of action 7: 87
plasma levels 7: 94
precautions 7: 97–98
reasons for use 7: 97
hyperthyroidism 7: 48–54
hypoglycaemic reactions 7: 126
libido 7: 101
liver disease: elimination 7: 45
metabolic effects 7: 30–33
metabolism 7: 41–42
pharmacology 7: 1–7
pharmacodynamics 7: 8–38
pharmacokinetics 7: 39–47
plasma binding 7: 43
plasma concentrations 7: 43–45, 94
plasma volume 7: 29
psychiatric effects 7: 100–101, 125
quinidine-like effect 7: 11–12
Raynaud's phenomenon 7: 101
renal disease: elimination 7: 45
renin activity, plasma 7: 30
respiratory function 7: 130–138
selectivity of activity 7: 12
side-effects 7: 98–102,
118–127, 130–137
determinants 7: 120–121
epidemiological studies 7: 122–124
severity 7: 120–121
sodium excretion, renal 7: 29–30
therapeutic use 7: 1–7
ventricular function 7: 26–27
weight gain 7: 102
Beta-blocking drugs
see β-adrenergic receptor blocking drugs
Bioavailability
beta-blocking drugs 7: 40–41
Breast Tumours
contraceptives oral 7: 143–144

C

Carbohydrate metabolism
beta-blocking drugs 7: 31–32
Cardiac failure
beta-blocking drugs 7: 99–100
Cardiomyopathy, hypertrophic
beta-blocking drugs 7: 107–109
Cholestyramine
paracetamol poisoning 7: 139
Condyloma acuminatum
treatment 7: 154–155
Contraceptives, oral
breast tumours 7: 143–144
gall-bladder disease 7: 143–144
haemolytic uraemic syndrome 7: 145
myocardial infarction 7: 142–143
thrombo-embolism, venous 7: 143–144

D

Depression
antidepressants, tricyclic: continuation 7: 147
beta-blocking drugs 7: 101
Diuretics
+ beta-blocking drugs in hypertension 7: 94
Drug interactions
guanethidine/chlorpromazine 7: 139
Drug reactions, adverse
beta-blocking drugs 7: 98–102,
118–127, 130–137
contraceptives, oral 7: 142–146
hospitalised patients 7: 146
Drug trials
beta-blocking drugs
angina pectoris 7: 59–61, 63–67, 73
hypertension 7: 89–90
Dyskinesia, tardive
antiparkinsonian drugs 7: 148

E

Erythropoiesis
androgens 7: 150–151

F

Fatty acids, free
beta-blocking drugs 7: 31–32

G

Gall-bladder disease
contraceptives oral 7: 143–144
Gonorrhoea
diagnosis in women 7: 156
Gout, pseudo
elderly 7: 151–152
Growth hormone
beta-blocking drugs 7: 32–33
Guanethidine
chlorpromazine interaction 7: 139

H

Haemolytic uraemic syndrome
contraceptives, oral 7: 145
Heart syndrome, hyperkinetic
beta-blocking drugs 7: 110–114
Hyperthyroidism
beta-blocking drugs 7: 48–54
Hypertension
beta-blocking drugs 7: 85–105
mild: treatment 7: 152–153
Hypoglycaemia
beta-blocking drugs 7: 126

I
Inpea
angina pectoris 7: 63
hypertension 7: 94
Isosorbide
angina pectoris
beta-blocking drugs comparison 7: 76–78

J
Joint disease, amyloid
treatment 7: 149

L
Libido
beta-blocking drugs 7: 101
Liver disease
beta-blocking drugs 7: 45
Lipid metabolism
drug action 7: 141–142
Lupus erythematosus
practolol 7: 102

M
Myocardial infarction
contraceptives, oral 7: 142–143

N
Nitrates
angina pectoris
beta-blocking drugs comparison 7: 76–78

O
Obesity
high-protein diet 7: 148–149
Oxprenolol
absorption 7: 40
angina pectoris 7: 61, 67
asthma 7: 132–136
bioavailability 7: 40–41
cardiomyopathy, hypertrophic 7: 107–109
clearance 7: 42–43
elimination 7: 40
half life, excretion 7: 42–43
heart syndrome, hyperkinetic 7: 110
hypertension 7: 91–92, 96–98
hyperthyroidism 7: 50
pharmacodynamics 7: 8–38
respiratory function 7: 130–136
side-effects 7: 98–102, 127

P
Paracetamol poisoning
charcoal 7: 139
cholestyramine 7: 139
Pindolol
absorption 7: 40
angina pectoris 7: 62, 72, 77
asthma 7: 132–136
bioavailability 7: 40–41
clearance 7: 42–43
elimination 7: 40
half-life, excretion 7: 42–43
hypertension 7: 93, 96–98
hyperthyroidism 7: 51
pharmacodynamics 7: 8–38
renal disease: elimination 7: 45
respiratory function 7: 130–136
side-effects 7: 98–102, 127
Practolol
absorption 7: 40
angina pectoris 7: 63, 73, 74–75
asthma 7: 132–136
bioavailability 7: 40–41
cardiomyopathy, hypertrophic 7: 107–109
clearance 7: 42–43
elimination 7: 40
half life, excretion 7: 42–43
heart syndrome, hyperkinetic 7: 114
hypertension 7: 91, 96–98
hyperthyroidism 7: 51
lupus erythematosus 7: 102
pharmacodynamics 7: 8–38
renal disease: elimination 7: 45
respiratory function 7: 130–136
side-effects 7: 98–102
Promethalol
angina pectoris 7: 61, 67
Fallot's tetralogy 7: 115
hyperthyroidism 7: 49
respiratory function 7: 134–135
Propranolol
absorption 7: 40
alcoholism 7: 140
angina pectoris 7: 61, 69–72, 74–78
asthma 7: 124–125, 132–136
bioavailability 7: 40–41
cardiac failure 7: 122
cardiomyopathy, hypertrophic 7: 107–109
clearance 7: 42–43
elimination 7: 40
Fallot's tetralogy 7: 114–115
haematological reactions 7: 126
half life, excretion 7: 42–43
heart syndrome, hyperkinetic 7: 110–114
hypertension 7: 90, 94, 96–98
hyperthyroid crisis 7: 52
hyperthyroidism 7: 49–50, 52–53
hypoglycaemic reactions 7: 126
metabolism 7: 41–42
pharmacodynamics 7: 8–38
plasma binding 7: 43
psychiatric effects 7: 100–101, 125
renal disease: elimination 7: 45
respiratory function 7: 130–136
side-effects 7: 98–102, 118–127, 130–137

R
Raynaud's phenomenon
beta-blocking drugs 7: 101
Renin secretion
beta-blocking drugs 7: 30
Renal disease
beta-blocking drugs 7: 45
Renal failure, acute
treatment 7: 155–156

Respiratory function
beta-blocking drugs 7: 130–138

S
Sodium excretion
beta-blocking drugs 7: 29–30
Sotalol
angina pectoris 7: 63, 72, 76
hypertension 7: 94
hyperthyroidism 7: 51
pharmacodynamics 7: 8–38

T
Thrombo-embolism
contraceptives, oral 7: 143–144
Tiprenolol
respiratory function 7: 134–135

V
Vasodilators
+ beta-blocking drugs in hypertension 7: 94
Verapamil
angina pectoris
beta-blocking drugs comparison 7: 78

W
Weight gain
beta-blocking drugs 7: 102

Pharmacology

International Journal of Experimental and Clinical Pharmacology

---

Editors:
B.B. Brodie (Bethesda, Md.); *R. Domenjoz* (Bonn), and *E. Vesell* (Hershey, Pa.)

Pharmacology publishes valuable information from the vast range of pharmacological studies and drug research. Relevant contributions from both experimental and clinical research, as well as papers on classical pharmacology, are regularly published. In addition, articles concerned with a number of specialised areas are also featured, such as molecular pharmacology, biochemical pharmacology, neuropsychopharmacology, toxicology, pharmacogenetics and clinical pharmacology. *Pharmacology* is a successor to *Medicina et Pharmacologia Experimentalis*, founded in 1959.

Subscription data:
Pharmacology appears monthly in numbers of approximately 64 pages each. 2 annual volumes of 6 numbers each. Subscription price per volume is SFr. 96.– / US $ 35.00 / DM 91.–, postage included.



S. Karger
Basel · München · Paris · London
New York · Sydney

KI 73096

Australian Drug Compendium 1973-74

8th edition just published

Valuable for every doctor

Contents:

Comprehensive and detailed prescribing information on the most commonly prescribed drugs.
Guide to clinically significant drug interactions.
Basic or quick reminder details of every pharmaceutical product available in Australia.
Every solid dosage form illustrated. A unique system as an aid to the identification of prescription preparations.

Other Editorial Features:

Proprietary Medicines Index; Medical Films Directory; Guide to the Calculation of Drug Dosage in Children; Medical and Scientific Information and Tables; Manufacturers' Directory.

Hard Cover - 684 pages

Price: $Aust.11.00, $US16.50, Stg.6.75 (plus $A1.00 or equivalent, packing and postage)

TO: ADC Publications, PO Box 194, Balgowlah, N.S.W., 2093 Australia

- ☐ Please supply . . . copy/copies of the Australian Drug Compendium 1973–74
- ☐ Cheque or Bank Draft for . . . . . enclosed
- ☐ Please Bill my/our account. (Cross out whichever not applicable. Publisher pays packing and postal charges if remittance enclosed)

Please record my/our order for copy/copies of future editions.

Name . . . . . .

Address . . . . . .

. . . . . .

. . . . . .

Zip code . . . . . .